MedDataX Logo

Ketamine-midazolam as a Sedative Agent in Endoscopic Retrograde Cholangiopancreatography.

NCT06111872 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2025-03-25

No results posted yet for this study

Summary

Does Ketamine-Midazolam have a better efficacy and safety profile compared to Midazolam - Pethidine in Endoscopic Retrograde Cholangiopancreatography (ERCP)?

Conditions

  • Cholangitis
  • Pancreatic Cancer
  • Choledocholithiasis
  • Choledochal Cyst

Interventions

DRUG

Ketamine

Administration described in arm/ group description

DRUG

Midazolam

Administration described in arm/ group description

DRUG

Pethidin

Administration described in arm/ group description

Sponsors & Collaborators

  • National University of Malaysia

    lead OTHER

Principal Investigators

  • Azlanudin Azman · Universiti Kebangsaan Malaysia Medical Centre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-18
Primary Completion
2024-02-27
Completion
2024-10-25

Countries

  • Malaysia

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06111872 on ClinicalTrials.gov